IL280473A - 1H-pyrazolo[4,3-d]pyrimidine compounds as TOLL-LIKE 7 (TLR7) receptor agonists and their methods and uses - Google Patents
1H-pyrazolo[4,3-d]pyrimidine compounds as TOLL-LIKE 7 (TLR7) receptor agonists and their methods and usesInfo
- Publication number
- IL280473A IL280473A IL280473A IL28047321A IL280473A IL 280473 A IL280473 A IL 280473A IL 280473 A IL280473 A IL 280473A IL 28047321 A IL28047321 A IL 28047321A IL 280473 A IL280473 A IL 280473A
- Authority
- IL
- Israel
- Prior art keywords
- tlr7
- pyrazolo
- toll
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714238P | 2018-08-03 | 2018-08-03 | |
| US16/527,802 US11554120B2 (en) | 2018-08-03 | 2019-07-31 | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| PCT/US2019/044575 WO2020028608A1 (en) | 2018-08-03 | 2019-08-01 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280473A true IL280473A (en) | 2021-03-01 |
Family
ID=67742964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280473A IL280473A (en) | 2018-08-03 | 2021-01-28 | 1H-pyrazolo[4,3-d]pyrimidine compounds as TOLL-LIKE 7 (TLR7) receptor agonists and their methods and uses |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11554120B2 (enExample) |
| EP (2) | EP3830090B1 (enExample) |
| JP (4) | JP7337909B2 (enExample) |
| KR (2) | KR20210039411A (enExample) |
| CN (2) | CN112513046A (enExample) |
| AR (1) | AR115885A1 (enExample) |
| AU (1) | AU2019314444A1 (enExample) |
| BR (1) | BR112021001503A2 (enExample) |
| CA (1) | CA3108512A1 (enExample) |
| CL (1) | CL2021000216A1 (enExample) |
| CO (1) | CO2021000942A2 (enExample) |
| EA (1) | EA202190442A1 (enExample) |
| ES (2) | ES2941768T3 (enExample) |
| IL (1) | IL280473A (enExample) |
| MX (1) | MX2021001311A (enExample) |
| PE (1) | PE20211812A1 (enExample) |
| SG (1) | SG11202101031XA (enExample) |
| TW (1) | TW202019933A (enExample) |
| WO (2) | WO2020028608A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY188749A (en) * | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| CA3108519A1 (en) | 2018-08-03 | 2020-04-30 | Cadent Therapeutics, Inc. | Heteroaromatic nmda receptor modulators and uses thereof |
| US11554120B2 (en) * | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| EP4097105A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132593A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| US20230144824A1 (en) * | 2020-01-27 | 2023-05-11 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| CN115151546A (zh) * | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物 |
| JP2023512204A (ja) * | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| US20230122249A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP2023512207A (ja) * | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| WO2021247809A1 (en) * | 2020-06-04 | 2021-12-09 | Merck Sharp & Dohme Corp. | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS |
| CN114805392A (zh) * | 2021-01-20 | 2022-07-29 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| WO2022237884A1 (zh) * | 2021-05-13 | 2022-11-17 | 清华大学 | 一种抗体药物偶联物及其制备方法和应用 |
| GEAP202616883A (en) * | 2023-05-18 | 2026-03-25 | Merck Sharp & Dohme Llc | Compounds and adjuvant formulations useful in pneumococcal vaccines |
| CR20250503A (es) * | 2023-05-18 | 2026-01-12 | Merck Sharp & Dohme Llc | Compuestos y formulaciones útiles como adyuvantes de vacunas |
| CN121693509A (zh) * | 2023-06-07 | 2026-03-17 | 维申医药(南通)有限公司 | Toll样受体激动剂杂环类衍生物及其制备和应用 |
| CN119462640A (zh) * | 2023-07-24 | 2025-02-18 | 北京森妙生物科技有限公司 | 吡啶[3,2-d]嘧啶-2-胺衍生物及其制备方法和应用 |
| WO2025188694A1 (en) * | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Tricyclic tlr7 agonists and uses thereof |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| TW552261B (en) | 1996-07-03 | 2003-09-11 | Japan Energy Corp | Novel purine derivative |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7402556B2 (en) | 2000-08-24 | 2008-07-22 | Medarex, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| US7571211B1 (en) | 2002-04-15 | 2009-08-04 | Lightwaves Systems, Inc. | Method for routing messages over a network based on location |
| JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| US6897034B2 (en) | 2001-06-11 | 2005-05-24 | Medarex, Inc. | CD10-activated prodrug compounds |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| JP4562395B2 (ja) | 2002-01-09 | 2010-10-13 | メダレックス， インク． | Ｃｄ３０に対するヒトモノクローナル抗体 |
| KR101111085B1 (ko) | 2002-09-27 | 2012-04-12 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 화합물 및 그 용도 |
| JP2004137157A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | 新規アデニン誘導体を有効成分として含有する医薬 |
| TW200510454A (en) | 2003-04-15 | 2005-03-16 | Smithkline Beecham Corp | Conjugates comprising human IL-18 and substitution mutants thereof |
| JP4680902B2 (ja) | 2003-07-22 | 2011-05-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Ｒｇ１抗体及びその使用 |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| KR101374514B1 (ko) | 2003-12-10 | 2014-03-13 | 메다렉스, 인코포레이티드 | Ｉｐ―１０ 항체 및 그의 용도 |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINVERBINDUNG |
| US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JP2008517994A (ja) * | 2004-10-28 | 2008-05-29 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 新規医薬品 |
| CN101160324B (zh) | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| MX2007009878A (es) | 2005-02-18 | 2007-10-03 | Medarex Inc | Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep). |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| MX2007013780A (es) | 2005-05-04 | 2008-02-05 | Pfizer Ltd | Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c. |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| SI1912671T1 (en) | 2005-07-18 | 2018-01-31 | Seattle Genetics, Inc. | Conjugates beta-glucuronide linker-drug |
| MX2008002414A (es) | 2005-09-02 | 2008-03-27 | Pfizer | 1h-imidazopiridinas sustituidas con hidroxi y procedimientos. |
| US20090105212A1 (en) | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| CN101365679B (zh) | 2005-10-26 | 2012-11-14 | 梅达莱克斯公司 | 制备cc-1065类似物的方法和化合物 |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| AU2006321841C1 (en) | 2005-12-08 | 2013-01-24 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use |
| NZ568015A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
| JP2009528989A (ja) | 2006-02-17 | 2009-08-13 | ファイザー・リミテッド | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 |
| AU2007325952B8 (en) | 2006-06-29 | 2013-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free synthesis of proteins containing unnatural amino acids |
| EP2054436A1 (en) | 2006-08-18 | 2009-05-06 | Novo Nordisk Health Care AG | Transglutaminase variants with improved specificity |
| US20100093082A1 (en) | 2006-09-08 | 2010-04-15 | Ambrx, Inc. | Site Specific Incorporation of Non-Natural Amino Acids by Vertebrate Cells |
| ES2625798T3 (es) | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| EP2097097B1 (en) | 2006-12-01 | 2018-05-30 | E. R. Squibb & Sons, L.L.C. | Antibodies, in particular human antibodies, that bind cd22 and uses thereof |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| ES2456964T3 (es) | 2007-02-07 | 2014-04-24 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| KR20090122439A (ko) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | 단일 아미노산을 갖는 화학적 링커 및 이의 접합체 |
| JP2010518842A (ja) | 2007-02-22 | 2010-06-03 | ノボ ノルディスク ヘルス ケア アーゲー | 改善された特異性を有するトランスグルタミナーゼ変異体 |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| AU2008231384B2 (en) | 2007-03-23 | 2011-09-15 | Amgen Inc. | Heterocyclic compounds and their use |
| SI2170888T1 (sl) | 2007-06-29 | 2015-10-30 | Gilead Sciences, Inc. | Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7 |
| CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| SI2195017T1 (sl) | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| WO2010093436A2 (en) | 2009-02-11 | 2010-08-19 | Carson Dennis A | Toll-like receptor modulators and treatment of diseases |
| MX2012004706A (es) | 2009-10-22 | 2012-06-08 | Gilead Sciences Inc | Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales. |
| EP2563366A4 (en) | 2010-04-30 | 2013-11-20 | Univ California | USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS |
| EP2563401A1 (en) | 2010-04-30 | 2013-03-06 | Telormedix SA | Methods for inducing an immune response |
| WO2011134668A1 (en) | 2010-04-30 | 2011-11-03 | Telormedix Sa | Phospholipid drug analogs |
| WO2012038058A1 (en) | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2012122396A1 (en) | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| UA116083C2 (uk) | 2011-11-09 | 2018-02-12 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні пурину для лікування вірусних інфекцій |
| PT2872515T (pt) | 2012-07-13 | 2016-07-27 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para o tratamento de infeções virais |
| MX359671B (es) | 2012-08-24 | 2018-10-05 | Glaxosmithkline Llc Star | Compuestos de pirazolopiridina. |
| EA035327B1 (ru) | 2012-10-10 | 2020-05-28 | Янссен Сайенсиз Айрлэнд Юси | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний |
| EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
| LT2956173T (lt) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulizino junginiai, gavimo ir panaudojimo būdai |
| US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| CN105338983B (zh) | 2013-03-29 | 2019-10-25 | 爱尔兰詹森科学公司 | 用于治疗病毒感染的大环脱氮-嘌呤酮 |
| JP6763769B2 (ja) | 2013-06-27 | 2020-09-30 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染症および他の疾病の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体 |
| US20160199499A1 (en) | 2013-08-16 | 2016-07-14 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
| WO2015036044A1 (en) | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
| WO2015157504A1 (en) * | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
| SG11201608299TA (en) | 2014-05-01 | 2016-11-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
| KR102139847B1 (ko) | 2014-05-01 | 2020-07-31 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
| WO2015171527A1 (en) * | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| CN106459048A (zh) * | 2014-05-14 | 2017-02-22 | 辉瑞公司 | 吡唑并吡啶类和吡唑并嘧啶类 |
| MX386981B (es) | 2014-08-15 | 2025-03-19 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| ES2736106T3 (es) | 2015-03-10 | 2019-12-26 | Bristol Myers Squibb Co | Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos |
| AU2016293441A1 (en) * | 2015-07-15 | 2018-02-01 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as IRAK-4 inhibitors |
| JP2018531935A (ja) | 2015-10-02 | 2018-11-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗体を結合させるためのトランスグルタミナーゼバリアント |
| SG11201802769RA (en) | 2015-10-29 | 2018-05-30 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| CN108349982B (zh) | 2015-11-05 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物 |
| US20170166384A1 (en) | 2015-12-11 | 2017-06-15 | Graphic Packaging International, Inc. | Container with absorption features |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US20190263804A1 (en) | 2016-06-16 | 2019-08-29 | Janssen Pharmaceutica Nv | Azabenzimidazole derivatives as pi3k beta inhibitors |
| CN109715214B (zh) * | 2016-09-13 | 2022-03-04 | 豪夫迈·罗氏有限公司 | Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗 |
| KR20190084991A (ko) | 2016-11-28 | 2019-07-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피라졸로-헤테로아릴 유도체, 이의 제조 방법 및 의학적 용도 |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US12226480B2 (en) | 2017-12-21 | 2025-02-18 | Sumitomo Pharma Co., Ltd. | Combination drug including TLR7 agonist |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| US11554120B2 (en) * | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| US11664120B1 (en) * | 2020-05-11 | 2023-05-30 | Walgreen Co. | Apparatuses, systems, and methods for reducing return of prescriptions to stock |
-
2019
- 2019-07-31 US US16/527,802 patent/US11554120B2/en active Active
- 2019-08-01 PE PE2021000126A patent/PE20211812A1/es unknown
- 2019-08-01 MX MX2021001311A patent/MX2021001311A/es unknown
- 2019-08-01 WO PCT/US2019/044575 patent/WO2020028608A1/en not_active Ceased
- 2019-08-01 AU AU2019314444A patent/AU2019314444A1/en not_active Abandoned
- 2019-08-01 KR KR1020217005766A patent/KR20210039411A/ko not_active Ceased
- 2019-08-01 ES ES19758854T patent/ES2941768T3/es active Active
- 2019-08-01 JP JP2021505870A patent/JP7337909B2/ja active Active
- 2019-08-01 EP EP19759090.4A patent/EP3830090B1/en active Active
- 2019-08-01 SG SG11202101031XA patent/SG11202101031XA/en unknown
- 2019-08-01 EP EP19758854.4A patent/EP3830089B1/en active Active
- 2019-08-01 US US16/529,457 patent/US11400094B2/en active Active
- 2019-08-01 CN CN201980051044.8A patent/CN112513046A/zh active Pending
- 2019-08-01 EA EA202190442A patent/EA202190442A1/ru unknown
- 2019-08-01 CA CA3108512A patent/CA3108512A1/en active Pending
- 2019-08-01 AR ARP190102180A patent/AR115885A1/es not_active Application Discontinuation
- 2019-08-01 CN CN201980062888.2A patent/CN112752759A/zh active Pending
- 2019-08-01 WO PCT/US2019/044578 patent/WO2020028610A1/en not_active Ceased
- 2019-08-01 KR KR1020217005765A patent/KR20210039410A/ko not_active Ceased
- 2019-08-01 ES ES19759090T patent/ES2941520T3/es active Active
- 2019-08-01 BR BR112021001503-5A patent/BR112021001503A2/pt not_active Application Discontinuation
- 2019-08-01 JP JP2021505800A patent/JP7337907B2/ja active Active
- 2019-08-02 TW TW108127543A patent/TW202019933A/zh unknown
-
2021
- 2021-01-27 CL CL2021000216A patent/CL2021000216A1/es unknown
- 2021-01-28 CO CONC2021/0000942A patent/CO2021000942A2/es unknown
- 2021-01-28 IL IL280473A patent/IL280473A/en unknown
-
2022
- 2022-12-14 US US18/081,558 patent/US20230140047A1/en not_active Abandoned
-
2023
- 2023-08-23 JP JP2023135513A patent/JP2023179420A/ja active Pending
- 2023-08-23 JP JP2023135510A patent/JP2023182569A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202101031XA (en) | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL288080A (en) | A process for the preparation of h7-pyrrolo[3,2-d]pyrimidine derivatives and their artificial intermediates | |
| IL265918B (en) | Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors | |
| IL260923B (en) | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| IL270909A (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| IL258231A (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| SG11201803605YA (en) | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND | |
| IL242162B (en) | Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists | |
| IL268923A (en) | History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity | |
| ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| EP3560931B8 (en) | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF | |
| EP3196199A4 (en) | Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor | |
| EP3459953A4 (en) | NEW 5H-PYRROLO [2,3-D] PYRIMIDIN-6 (7H) -ONE DERIVATIVE | |
| ZA201804871B (en) | Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds | |
| PT3330271T (pt) | Composto de pirrolo[2,3-d]pirimidina ou sal do mesmo |